| Market Cap | 268.21B | P/E | 20.64 | EPS this Y | 468.20% | Ern Qtrly Grth | 68.80% |
| Income | 2.31B | Forward P/E | 13.76 | EPS next Y | 14.80% | 50D Avg Chg | -4.00% |
| Sales | 61.4B | PEG | 0.23 | EPS past 5Y | -11.64% | 200D Avg Chg | -3.00% |
| Dividend | 3.00% | Price/Book | 5.73 | EPS next 5Y | 67.38% | 52W High Chg | -12.00% |
| Recommedations | 1.80 | Quick Ratio | - | Shares Outstanding | 2.53B | 52W Low Chg | 25.00% |
| Insider Own | 0.05% | ROA | - | Shares Float | 2.53B | Beta | - |
| Inst Own | 78.57% | ROE | - | Shares Shorted/Prior | 20.43M/23.16M | Price | 105.70 |
| Gross Margin | 74.71% | Profit Margin | 3.76% | Avg. Volume | 7,449,562 | Target Price | 138.98 |
| Oper. Margin | 36.51% | Earnings Date | Apr 25 | Volume | 10,865,850 | Change | 0.40% |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Truist Securities | Buy | Apr 26, 24 |
| Cantor Fitzgerald | Overweight | Apr 18, 24 |
| Berenberg | Buy | Apr 8, 24 |
| Cantor Fitzgerald | Overweight | Apr 5, 24 |
| Cantor Fitzgerald | Overweight | Apr 1, 24 |
| Truist Securities | Buy | Mar 28, 24 |
| Cantor Fitzgerald | Overweight | Mar 27, 24 |
| Wells Fargo | Equal-Weight | Mar 27, 24 |
| Societe Generale | Sell | Mar 11, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Oosthuizen Johannes Jacobus | President, U.S. Mark.. President, U.S. Market | Nov 09 | Sell | 102.3841 | 2,081 | 213,061 | 18,191 | 11/13/23 |
| DeLuca Richard R. | EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth | Nov 08 | Sell | 105.0286 | 43,823 | 4,602,668 | 111,764 | 11/09/23 |
| Oosthuizen Johannes Jacobus | President, U.S. Mark.. President, U.S. Market | Oct 30 | Option | 102.82 | 915 | 94,080 | 20,723 | 10/31/23 |
| Davis Robert M | Chairman, CEO & Pres.. Chairman, CEO & President | Apr 28 | Sell | 114.93 | 143,329 | 16,472,802 | 271,817 | 04/28/23 |
| Davis Robert M | Chairman, CEO & Pres.. Chairman, CEO & President | Apr 28 | Option | 56.04 | 143,329 | 8,032,157 | 415,146 | 04/28/23 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD Exe V-P & Pres. MMD | Apr 13 | Sell | 115.07 | 134,055 | 15,425,709 | 04/14/23 | |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD Exe V-P & Pres. MMD | Apr 13 | Option | 59.06 | 134,055 | 7,917,288 | 134,055 | 04/14/23 |
| Romanelli Joseph | President, Human Hea.. President, Human Health Int?l | Feb 15 | Sell | 108.2201 | 5,000 | 541,100 | 20,284 | 02/16/23 |
| MIZELL STEVEN | EVP, Chief HR Office.. EVP, Chief HR Officer | Feb 13 | Sell | 109.1003 | 1,815 | 198,017 | 33,085 | 02/14/23 |
| MIZELL STEVEN | EVP, Chief HR Office.. EVP, Chief HR Officer | Feb 09 | Sell | 107.0013 | 5,000 | 535,006 | 34,900 | 02/10/23 |
| MIZELL STEVEN | EVP, Chief HR Office.. EVP, Chief HR Officer | Feb 06 | Sell | 104.2546 | 4,436 | 462,473 | 39,900 | 02/08/23 |
| Oosthuizen Johannes Jacobus | President, U.S. Mark.. President, U.S. Market | Nov 09 | Sell | 103.21 | 1,795 | 185,262 | 16,731 | 11/10/22 |
| Davis Robert M | CEO & President CEO & President | Nov 09 | Option | 0 | 167,613 | 415,206 | 11/10/22 | |
| Davis Robert M | CEO & President CEO & President | Nov 09 | Sell | 102.84 | 167,613 | 17,237,321 | 247,593 | 11/10/22 |
| FRAZIER KENNETH C | Executive Chair Executive Chair | Nov 07 | Option | 0 | 235,769 | 936,422 | 11/08/22 | |
| FRAZIER KENNETH C | Executive Chair Executive Chair | Nov 07 | Sell | 99.31 | 235,769 | 23,414,219 | 700,653 | 11/08/22 |
| Oosthuizen Johannes Jacobus | SVP, U.S. Market SVP, U.S. Market | May 03 | Option | 87.1 | 907 | 79,000 | 14,961 | 05/05/22 |
| Garay Arpa | SVP Human Health Glo.. SVP Human Health Global Mktg. | May 03 | Option | 87.1 | 907 | 79,000 | 2,368 | 05/05/22 |
| Karachun Rita A | Sr. VP Fince-Global.. Sr. VP Fince-Global Controller | May 03 | Option | 87.1 | 949 | 82,658 | 41,429 | 05/05/22 |
| Klobuchar Michael A | EVP - Chief Strategy.. EVP - Chief Strategy Officer | May 03 | Option | 87.1 | 885 | 77,084 | 15,775 | 05/05/22 |
| LeCointe-Cephas Lisa | SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer | May 03 | Option | 87.1 | 813 | 70,812 | 3,943 | 05/05/22 |
| Litchfield Caroline | EVP & CFO EVP & CFO | May 03 | Option | 87.65 | 773 | 67,753 | 27,799 | 05/04/22 |
| Li Dean Y | Executive VP & Presi.. Executive VP & President, MRL | May 03 | Option | 87.65 | 773 | 67,753 | 16,839 | 05/04/22 |
| Williams David Michael | EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer | May 03 | Option | 87.65 | 427 | 37,427 | 9,410 | 05/04/22 |
| Williams David Michael | EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer | Feb 10 | Option | 76.53 | 1,202 | 91,989 | 7,421 | 02/14/22 |
| Clyburn Frank | EVP & Pres ? Human H.. EVP & Pres ? Human Health | Oct 30 | Option | 29.35 | 42,120 | 1,236,222 | 136,857 | 11/02/21 |
| Clyburn Frank | EVP & Pres ? Human H.. EVP & Pres ? Human Health | Oct 30 | Sell | 87.87 | 39,762 | 3,493,887 | 97,095 | 11/02/21 |
| DeLuca Richard R. | EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth | Oct 29 | Option | 0 | 135,405 | 252,335 | 11/02/21 | |
| DeLuca Richard R. | EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth | Oct 29 | Sell | 87.56 | 135,405 | 11,856,062 | 116,930 | 11/02/21 |
| Karachun Rita A | Sr. VP Fince-Global.. Sr. VP Fince-Global Controller | May 06 | Option | 75.98 | 1,212 | 92,088 | 36,215 | 05/06/21 |
| LeCointe-Cephas Lisa | SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer | May 06 | Option | 75.98 | 694 | 52,730 | 2,612 | 05/06/21 |
| MIZELL STEVEN | EVP, Chief HR Office.. EVP, Chief HR Officer | Nov 03 | Option | 75.89 | 4,574 | 347,121 | 7,624 | 11/03/20 |
| Davis Robert M | EVP, Global Svcs & C.. EVP, Global Svcs & CFO | Oct 06 | Option | 0 | 251,273 | 422,329 | 10/06/20 | |
| Davis Robert M | EVP, Global Svcs & C.. EVP, Global Svcs & CFO | Oct 06 | Sell | 81.03 | 251,273 | 20,360,651 | 171,056 | 10/06/20 |